BFM
PTHS

Boothbay Fund Management’s Pelthos Therapeutics PTHS Stock Holding History

Boothbay Fund Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
81,858
+1,178
+1% +$27.9K 0.02% 690
2025
Q4 		$2.5M Buy
80,680
+59,435
+280% +$1.71M 0.04% 495
2025
Q3 		$595K Buy
+21,245
New +$516K 0.01% 1060
2025
Q2 		– Sell
-13,075
Closed -$186K – 1820
2025
Q1 		$186K Buy
+13,075
New +$224K ﹤0.01% 1177

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Boothbay Fund Management's PTHS Position: Q1 2026 in Review

Boothbay Fund Management increased its Pelthos Therapeutics (PTHS) stake by 1.5% in Q1 2026, buying an estimated $27.9K and bringing the position to 81,858 shares worth $1.72M. The position accounts for 0.02% of the portfolio, ranked #690.

Boothbay Fund Management first reported a position in PTHS in Q1 2025 and has held it in 4 quarters since. The position peaked at $2.5M in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Boothbay Fund Management held 81,858 shares of Pelthos Therapeutics worth $1.72M as of Q1 2026.
  • Boothbay Fund Management bought 1,178 Pelthos Therapeutics shares in Q1 2026, an estimated $27.9K.
  • Pelthos Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q1 2026, its #690 holding.
  • Boothbay Fund Management first reported a position in Pelthos Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Boothbay Fund Management's Pelthos Therapeutics position peaked at $2.5M in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.